Independent Financial Group LLC Invests $712,000 in Edwards Lifesciences Corporation $EW

Independent Financial Group LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the first quarter, HoldingsChannel reports. The firm bought 8,886 shares of the medical research company’s stock, valued at approximately $712,000.

Other hedge funds also recently made changes to their positions in the company. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $26,000. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences in the 1st quarter worth about $25,000. Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences during the 4th quarter valued at about $27,000. JPL Wealth Management LLC purchased a new position in Edwards Lifesciences during the 3rd quarter valued at about $25,000. Finally, Hilton Head Capital Partners LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth about $28,000. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the sale, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. The trade was a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of recent research reports. BTIG Research upped their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research note on Wednesday, April 1st. Finally, Robert W. Baird raised their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $98.95.

Edwards Lifesciences Stock Down 0.7%

NYSE:EW opened at $84.41 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The firm has a market cap of $48.61 billion, a P/E ratio of 44.90, a P/E/G ratio of 2.13 and a beta of 0.86. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a 50-day simple moving average of $87.60 and a two-hundred day simple moving average of $83.91.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.